FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Inclusion Criteria:

Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy
Primary tumor 2.0 cm or greater, and/or clinical evidence of axillary disease (palpable N1 or N2 or biopsy proven)
No obvious contraindications for primary chemotherapy
Able to lie still for PET and MRI scanning
Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines

Exclusion Criteria:

Serious systemic illness other than breast cancer
Contraindication to MRI or history of adverse reaction to gadolinium
Evidence of distant disease outside of regional lymph nodes
Pregnant
Poorly controlled diabetes mellitus (fasting blood glucose > 200)
Prior systemic cancer therapy